ER

Novelos enrolls first patient in solid tumor imaging trial

Thursday, October 25, 2012 09:48 AM

Novelos Therapeutics, a pharmaceutical company developing novel drugs for the treatment and diagnosis of cancer, announced that the University of Wisconsin Carbone Cancer Center (UWCCC), an oncology research institution, has enrolled the first patient in a phase I/II positron emission tomography (PET) imaging trial of I-124-CLR1404 (LIGHT), a cancer-targeted PET imaging agent, in patients with nine solid tumor types, including triple negative breast, soft tissue sarcoma, colorectal, gastric, head and neck cancer, esophageal, prostate, ovarian and pancreatic.

More... »

Aclaris raises $21M in Series A Financing

Thursday, October 25, 2012 07:30 AM

Aclaris Therapeutics, a privately held specialty pharmaceutical company focused on dermatological therapeutics, has secured $21 million in Series A financing.

More... »

PFF calls for letters of intent for 2013 Young Investigator and Established Investigator awards

Wednesday, October 24, 2012 10:11 AM

The Pulmonary Fibrosis Foundation (PFF) is accepting letters of intent for its 2013 PFF Research Fund grants.  Letters of intent will be accepted until Monday, November 26.  

More... »

Bayer’s riociguat meets primary endpoint in phase III study in PAH

Tuesday, October 23, 2012 07:15 AM

Bayer HealthCare Pharmaceuticals, the U.S.-based pharmaceuticals business of Bayer HealthCare, issued data from the phase III PATENT-1 pulmonary arterial hypertension (PAH) trial evaluating its investigational drug riociguat in both treatment-naive patients and those pre-treated with an endothelin receptor antagonist or an oral, inhaled or subcutaneous prostanoid.

More... »

Pfizer to acquire NextWave Pharmaceuticals

Monday, October 22, 2012 12:56 PM

Pfizer, a global research-based pharmaceutical company, has agreed to acquire NextWave Pharmaceuticals, a privately-held, specialty pharmaceutical company focused on attention deficit/hyperactivity disorder (ADHD) and related central nervous system (CNS) disorders.

More... »

Charles River Labs, AZ enter strategic partnership

Monday, October 22, 2012 10:43 AM

AstraZeneca, a global biopharmaceutical company, has selected Charles River Laboratories International, a global provider of research products and services, as its preferred strategic partner for outsourced regulated safety assessment and development DMPK (drug metabolism and pharmacokinetics).

More... »

Venture capital investments decline in dollars and deal volume in Q3 2012

Friday, October 19, 2012 03:26 PM

Venture capitalists invested $6.5 billion in 890 deals in the third quarter of 2012, according to the MoneyTree Report from PricewaterhouseCoopers (PwC) and the National Venture Capital Association (NVCA), based on data provided by Thomson Reuters.

More... »

Resverlogix initiates phase II trial of RVX-208 in pre-diabetes

Friday, October 19, 2012 03:20 PM

Resverlogix, a Canadian clinical stage cardiovascular company, has initiated an exploratory phase II clinical trial in patients with pre-diabetes mellitus to examine the effects of RVX-208 and ApoA-I production on glucose metabolism.

More... »

Omeros adds two new vice presidents to management team

Friday, October 19, 2012 02:21 PM

Omeros, a Seattle, Wash.-based clinical-stage biopharmaceutical company targeting inflammation, coagulopathies and disorders of the central nervous system, has appointed two new vice presidents: Cathy Melfi, Ph.D. as vice president, regulatory affairs and quality systems, and Albert Yu, M.D., as vice president, clinical development.

More... »

Steris acquires businesses, expands healthcare service business

Friday, October 19, 2012 01:42 PM

Steris, an infection prevention, decontamination, surgical and critical care company based in Mentor, Ohio, purchased two privately-owned businesses: Spectrum Surgical Instruments of Stow, Ohio, and Total Repair Express (TRE) of Hillsborough, N.J.—both providers of surgical instrument repair services and instrument care products to hospitals and surgery centers in the U.S.

More... »